2019 Tuberculosis Drug Discovery and Development GRC: Shortening the Duration of Tuberculosis Chemotherapy and GRS

2019结核病药物发现与开发GRC：缩短结核病化疗和GRS的持续时间

基本信息

批准号：
9750348
负责人：
Mary Jackson
金额：
$ 0.6万
依托单位：
GORDON RESEARCH CONFERENCES
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-06-04 至 2019-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9750348
关键词：
Academia Address Adherence Bacteria Cause of Death Chemistry Clinic Clinical Research Clinical Trials Collaborations Communities Disease Drug Transport Drug resistance Elements Ensure Environment Epidemic Evaluation Face Fostering Future Goals Growth Hour Industry Infection Infectious Agent International Medicine Microbiology Outcome Participant Patients Performance Pharmaceutical Preparations Pharmacology Property Public Health Publishing Regimen Research Research Personnel Safety Science Scientist Site Spain Treatment Protocols Tuberculosis Underrepresented Minority Update Woman Work base bench to bedside career career development chemotherapy collaborative environment combat data exchange design drug development drug discovery meetings preclinical development programs research clinical testing symposium treatment duration tuberculosis chemotherapy tuberculosis drugs

项目摘要

Abstract This application seeks partial support for the 2019 Tuberculosis (TB) Drug Discovery & Development Gordon Research Conference (GRC) and Gordon Research Seminar (GRS) to be held in at the Rey Don Jaime Grand Hotel in Castelldefels, Spain from July 6-7 and 7-12, 2019. This will be the tenth GRC on TB Drug discovery with the first being held in 2001 and thereafter on a biennial basis and the fourth GRS associated with this GRC. This is the most important global conference on tuberculosis drug discovery and has consistently received a high-performance rating in the GRC Conference Evaluation outcome with more than 70% of conferees rating this meeting above average over the years. This GRC brings together TB drug development researchers from academia and industry in a friendly highly interactive environment to focus on the challenge of combatting this global public health threat. TB is now the leading cause of death internationally due to a single infectious agent despite the availability of a 6-9 month treatment regimen that achieves ~83% cure rates. This GRC has been assembled around the concept that the WHO's strategy to end the global TB epidemic can only be achieved by developing regimens with dramatically reduced treatment durations. A shorter treatment duration with drugs of similar of preferably increased safety profiles will lead to better adherence and importantly, combat the emerging threat of drug resistance. Under the theme of treatment shortening, this conference will bring together investigators with diverse backgrounds, including microbiology, chemistry, pharmacology, medicine and clinical research. The sessions have been orchestrated to provide a bench-to-bedside view of critical elements in achieving treatment shortening in the TB drug discovery field. The GRC will provide a unique opportunity to bring together the world's leading TB drug discovery researchers as well as a few researchers from outside the field who are doing work that may have a fundamental impact of how TB drug discovery may be approached in the future. The GRC and associated GRS foster an environment wherein which researchers are encouraged to share cutting edge unpublished data and exchange ideas between both established as well as young investigators and trainees hereby promoting career development for all attendees. The GRC will include a “Power Hour”, an optional informal gathering for all meeting participants to address the challenges women face in science and to support the professional growth of women in science. Both the GRC and the GRS programs will reflect the diversity of the scientists in the field with an aim of strong representation of women, underrepresented minorities and international scientists.

抽象的本申请寻求对 2019 年结核病 (TB) 药物发现与开发戈登的部分支持研究会议 (GRC) 和戈登研究研讨会 (GRS) 将在 Rey Don Jaime Grand 举行 2019 年 7 月 6 日至 7 日和 7 日至 12 日入住西班牙卡斯特尔德费尔斯酒店。这将是第十届关于结核病药物发现的 GRC，第一次于 2001 年举行，此后每两年举行一次基础和与此 GRC 相关的第四次 GRS 这是最重要的全球会议。结核病药物发现，并在 GRC 会议上持续获得高绩效评级超过 70% 的与会者对本次会议的评价结果高于历年平均水平。 GRC 将来自学术界和工业界的结核病药物开发研究人员聚集在一起，以高度友好的方式进行现在，互动环境重点关注抗击这一全球公共卫生威胁的挑战。尽管有 6-9 个月的可用时间，但单一传染源仍是国际上导致死亡的主要原因治愈率约为 83% 的治疗方案是围绕以下概念构建的。世卫组织结束全球结核病流行的战略只能通过制定具有显着效果的治疗方案来实现缩短治疗时间，使用类似的药物，最好提高安全性。配置文件将带来更好的依从性，更重要的是，对抗新出现的耐药性威胁。本次会议以缩短治疗为主题，将汇集不同领域的研究人员背景，包括微生物学、化学、药理学、医学和临床研究。精心策划，以提供实现治疗的关键要素的从实验室到临床的视角 GRC 将为结核病药物发现领域的缩短提供一个独特的机会。世界领先的结核病药物研发研究人员以及一些来自该领域之外的研究人员所做的工作可能对未来如何进行结核病药物发现产生根本性影响。 GRC 和相关的 GRS 营造了一个鼓励研究人员共享的环境最前沿的未发表数据，并在资深研究人员和年轻研究人员之间交流想法 GRC 将包括一个“Power Hour”活动，旨在促进所有参加者的职业发展。可选的全体会议非正式聚会，以解决妇女在科学领域面临的挑战并 GRC 和 GRS 计划都将反映支持科学界女性的职业发展。该领域科学家的多样性，旨在提高女性代表性，但代表性不足少数族裔和国际科学家。